Danaher (NYSE:DHR) PT Lowered to $260.00

Danaher (NYSE:DHR) had its price objective decreased by stock analysts at Evercore ISI from $266.00 to $260.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the conglomerate’s stock. Evercore ISI’s price objective would indicate a potential upside of 7.94% from the company’s current price.

Other research analysts have also recently issued reports about the company. Robert W. Baird upped their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. TD Cowen boosted their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Barclays boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. HSBC raised Danaher from a “hold” rating to a “buy” rating and boosted their target price for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, Bank of America boosted their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $268.67.

Danaher Stock Performance

DHR traded down $3.63 during trading on Tuesday, reaching $240.88. 1,215,946 shares of the company’s stock were exchanged, compared to its average volume of 2,845,540. The company’s fifty day simple moving average is $255.96 and its 200-day simple moving average is $246.75. The stock has a market capitalization of $178.42 billion, a P/E ratio of 40.83, a price-to-earnings-growth ratio of 3.82 and a beta of 0.84. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher has a 1 year low of $182.09 and a 1 year high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the business earned $2.36 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. As a group, research analysts predict that Danaher will post 7.63 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 148,783 shares of company stock worth $37,536,717. Corporate insiders own 10.90% of the company’s stock.

Institutional Trading of Danaher

A number of large investors have recently made changes to their positions in DHR. Alpine Global Management LLC purchased a new position in shares of Danaher during the 3rd quarter worth $1,489,000. Advisors Asset Management Inc. lifted its position in Danaher by 3.1% during the third quarter. Advisors Asset Management Inc. now owns 10,983 shares of the conglomerate’s stock worth $2,725,000 after buying an additional 331 shares during the period. Ameriprise Financial Inc. grew its holdings in Danaher by 6.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,633,999 shares of the conglomerate’s stock valued at $405,390,000 after buying an additional 102,647 shares during the period. Alps Advisors Inc. increased its stake in shares of Danaher by 441.1% during the 3rd quarter. Alps Advisors Inc. now owns 24,795 shares of the conglomerate’s stock valued at $6,152,000 after acquiring an additional 20,213 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its holdings in shares of Danaher by 23.1% during the 3rd quarter. Evergreen Capital Management LLC now owns 4,126 shares of the conglomerate’s stock worth $1,024,000 after acquiring an additional 775 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.